Erratum to: Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test (Journal of Hematology and Oncology (2017) 10 (152) DOI: 10.1186/s13045-017-0520-1);Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test

Journal of Hematology and Oncology

Volumn 10, Issue 1, 2017, Pages

  Hsueh, Eddy C ^a   Debloom, James R ^b   Lee, Jonathan ^c   Sussman, Jeffrey J ^d   Covington, Kyle R ^e   Middlebrook, Brooke ^e   Johnson, Clare ^e   Cook, Robert W ^e   Slingluff, Craig L ^f   McMasters, Kelly M ^g  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b South Carolina Skin Cancer Center   (United States)

^c Northside Melanoma and Sarcoma Specialists of Georgia   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e Castle Biosciences Incorporated   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g University of Louisville School of Medicine   (United States)

Author keywords

Cutaneous melanoma; DecisionDx Melanoma; Gene expression profiling; Metastasis; Prognosis; Staging

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BRESLOW THICKNESS; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; CUTANEOUS MELANOMA; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC RISK; MULTICENTER STUDY; OVERALL SURVIVAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; SENTINEL LYMPH NODE BIOPSY; SKIN DISEASE ASSESSMENT; SURVIVAL ANALYSIS; VERY ELDERLY; ADOLESCENT; CLINICAL TRIAL; GENETICS; MELANOMA; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; REGISTER; SKIN TUMOR; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 85028569028     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-017-0524-x     Document Type: Erratum

References (29)

1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-206.
2. Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-4.
3. Shaikh WR, Dusza SW, Weinstock MA, Oliveria SA, Geller AC, Halpern AC. Melanoma thickness and survival trends in the United States, 1989 to 2009. J Natl Cancer Inst. 2015; https://doi.org/10.1093/jnci/djv294.
4. Whiteman DC, Baade PD, Olsen CM. More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland. Aust J Invest Dermatol. 2015;135:1190-3.
5. Glazer AM, Winkelmann RR, Farberg AS, Rigel DS. Analysis of trends in US melanoma incidence and mortality. JAMA Dermatol. 2017;153:225-6.
6. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780-8.
7. Bhutiani N, Egger ME, McMasters KM. Optimizing follow-up assessment of patients with Cutaneous melanoma. Ann Surg Oncol. 2017;24:861-3.
8. Leon-Ferre RA, Kottschade LA, Block MS, McWilliams RR, Dronca RS, Creagan ET, et al. Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma. Melanoma Res. 2017; doi: 10.1097/CMR.0000000000000344.
9. Nishino M, Giobbie-Hurder A, Ramaiya NH, Hodi FS. Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. J Immunother Cancer. 2014; doi: 10.1186/s40425-014-0040-2.
10. Park TS, Phan GQ, Yang JC, Kammula U, Hughes MS, Trebska-McGowan K, et al. Routine computer tomography imaging for the detection of recurrences in high-risk melanoma patients. Ann Surg Oncol. 2017;24:947-51.
11. Podlipnik S, Carrera C, Sanchez M, Arguis P, Olondo ML, Vilana R, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American joint committee on cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol. 2016;75:516-24.
12. Gerami P, Cook RW, Wilkinson J, Russell MC, Dhillon N, Amaria RN, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res. 2015;21:175-83.
13. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12:461-8.
14. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205-9.
15. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res. 2007;13:806-15.
16. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406:536-40.
17. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005;102:6092-7.
18. Mauerer A, Roesch A, Hafner C, Stempfl T, Wild P, Meyer S, et al. Identification of new genes associated with melanoma. Exp Dermatol. 2011;20:502-7.
19. Scatolini M, Grand MM, Grosso E, Venesio T, Pisacane A, Balsamo A, et al. Altered molecular pathways in melanocytic lesions. Int J Cancer. 2010;126:1869-81.
20. Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther. 2005;4:1018-29.
21. Gerami P, Cook RW, Russell MC, Wilkinson J, Amaria RN, Gonzalez R, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015;72:780-5. e3
22. Zager JS, Gastman BR, Messina J, Sondak VK, Ferris L, Cook RW, et al. Performance of a 31-gene expression profile in a previously unreported cohort of 334 cutaneous melanoma patients. J Clin Oncol. 2016;34(Suppl 15):9581.
23. Burton AL, Egger ME, Gilbert JE, Stromberg AJ, Hagendoorn L, Martin RC, et al. Assessment of mitotic rate reporting in melanoma. Am J Surg. 2012;204:969-75.
24. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599-609.
25. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14:450-73.
26. Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, et al. Collaborative ocular oncology group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology. 2012;119:1596-603.
27. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
28. Kaufman H, Amatruda T, Nemunaitis JJ, Chesne JA, Delman KA, Spitler LE, et al. Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC). J Clin Oncol. 2015;33(Suppl 15):9074.
29. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600-9.